SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX ConferencePRNewsWire • 05/21/24
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical PracticePRNewsWire • 05/16/24
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial ResultsPRNewsWire • 05/10/24
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaPRNewsWire • 04/25/24
Soligenix surges as MarVax vaccine secures Orphan Drug Designation from FDAProactive Investors • 04/15/24
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionPRNewsWire • 04/15/24
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus InfectionPRNewsWire • 04/11/24
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines AgencyPRNewsWire • 04/03/24
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 01/26/24
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseasePRNewsWire • 01/08/24
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisPRNewsWire • 01/04/24
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg VirusesPRNewsWire • 01/02/24
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug DiscoveryPRNewsWire • 12/01/23
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's DiseasePRNewsWire • 11/30/23
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial ResultsPRNewsWire • 11/13/23